The deal adds to Evotec research funds and potential milestone payments associated with DeveloGen's discovery alliance with Boehringer Ingelheim on small molecules to treat type 2 diabetes.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.